Malpractice insurance costs and coverage denials skyrocket for clinics that provide gender-affirming care to minors; American Red Cross declares emergency as low blood supply puts strain on hospitals; Walgreens agrees to pay $360 million to Humana.
In the aftermath of several states banning gender-affirming care for minors, independent clinics and medical practices have stepped up in adjacent states to fill the void, but they are now facing significant difficulties obtaining malpractice insurance, according to Kaiser Health News. Nearly half the states have implemented restrictions on transgender health care for youth, making clinics more susceptible to litigation. Rising malpractice premiums and coverage denials have become a hidden barrier, hindering the provision of gender-affirming care, even in states with legal protections for such health care.
The US is grappling with a severe blood shortage, marked by the lowest number of blood donors in 2 decades and a 40% decline in donations through the American Red Cross over the past 20 years, according to CNN. A shortfall of nearly 7000 units occurred between Christmas and New Year's Day, and the shortage is expected to worsen due to a combination of harsh winter conditions and seasonal illnesses. The Red Cross warns of critically low supply levels across the country, leaving hospitals and patients in need, and is urging health care professionals and the public to donate blood as soon as possible to address the crisis.
Walgreens has reached a settlement with Humana to resolve a lawsuit filed in 2022 in which it sought to overturn a $642 million arbitration award won by the insurer, according to Reuters. Walgreens has now agreed to pay $360 million to Humana to settle this lawsuit. Humana had accused Walgreens of inflating prescription drug prices for over a decade, a claim that Walgreens denied. While the terms of the settlement were not disclosed, Walgreens still faces other drug-price overcharge claims, including some from Blue Cross Blue Shield plaintiffs; the company has pledged to "vigorously defend" itself.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More